tiprankstipranks
C4 Therapeutics (CCCC)
NASDAQ:CCCC
US Market

C4 Therapeutics (CCCC) Stock Forecast & Price Target

392 Followers
See the Price Targets and Ratings of:

CCCC Analyst Ratings

Moderate Buy
2Ratings
1 Buy
1 Hold
0 Sell
Based on 2 analysts giving stock ratings to
C4
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CCCC Stock 12 Month Forecast

Average Price Target

$11.00
▲(121.77% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for C4 Therapeutics in the last 3 months. The average price target is $11.00 with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 121.77% change from the last price of $4.96.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,5.378461538461538,6.096923076923077,6.815384615384616,7.533846153846154,8.252307692307692,8.970769230769232,9.68923076923077,10.407692307692308,11.126153846153846,11.844615384615384,12.563076923076924,13.281538461538462,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,5.147692307692308,5.635384615384615,6.1230769230769235,6.610769230769231,7.098461538461539,7.586153846153847,8.073846153846155,8.561538461538461,9.04923076923077,9.536923076923078,10.024615384615384,10.512307692307694,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,4.916923076923077,5.173846153846154,5.430769230769231,5.687692307692307,5.944615384615385,6.201538461538462,6.458461538461538,6.7153846153846155,6.972307692307693,7.229230769230769,7.486153846153846,7.743076923076924,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.48,"date":1686268800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.37,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$14.00Average Price Target$11.00Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$14.00
Buy
182.26%
Upside
Reiterated
03/04/24
C4 Therapeutics (CCCC) PT Raised to $14 at JefferiesJefferies analyst Biren Amin raised the price target on C4 Therapeutics (NASDAQ: CCCC) to $14.00 (from $11.00) while maintaining a Buy rating.
UBS
$18.00
Buy
262.90%
Upside
Reiterated
02/27/24
C4 Therapeutics (CCCC) PT Lowered to $18 at UBS, well funded, multiple catalysts - one to watch in 24UBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $18.00 (from $19.00) while maintaining a Buy rating.
Morgan Stanley
$8.00
Hold
61.29%
Upside
Reiterated
02/26/24
C4 Therapeutics (CCCC) PT Raised to $8 at Morgan StanleyMorgan Stanley analyst Terence Flynn raised the price target on C4 Therapeutics (NASDAQ: CCCC) to $8.00 (from $1.00) while maintaining a Equalweight rating.
J.P. Morgan
$7.00
Hold
41.13%
Upside
Reiterated
02/23/24
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (NASDAQ: CCCC), Halozyme (NASDAQ: HALO) and Eli Lilly & Co (NYSE: LLY)
BMO Capital
$19.00
Buy
283.06%
Upside
Reiterated
02/22/24
Strong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 Therapeutics
Leerink Partners
$14.00
Buy
182.26%
Upside
Reiterated
12/13/23
We mentioned “glimmers of hope” in our last CFT7455 (IKZF1/3 degrader) data readout note (here), and we would repeat that sentiment coming out of yesterday's CCCC investor call on the CFT7455 update in multiple myeloma (MM). Given the reset on the study with the new 14/14 dosing regimen, this data readout had small patient populations in both the monotherapy (n=22) and dexamethasone combination (n=9) arms. The data suggest that CFT7455 has early signs of activity and is potentially tolerable, facilitating evaluation of the asset in earlier lines of therapy and in combination. We acknowledge that these data are in a small patient population and are in dose escalation. As such, we await more mature data to provide clarity on the emerging adverse event (AEs) and efficacy profile, particularly as we approach optimized dosing.

Best Analysts Covering C4 Therapeutics

Which Analyst Should I Follow If I Want to Buy CCCC and Sell After:
1 Month
Etzer DaroutBMO Capital
Success Rate
4/12 ratings generated profit
33%
Average Return
+5.53%
reiterated a buy rating 4 months ago
Copying Etzer Darout's trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of +5.53% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Etzer DaroutBMO Capital
Success Rate
5/12 ratings generated profit
42%
Average Return
+41.05%
reiterated a buy rating 4 months ago
Copying Etzer Darout's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +41.05% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Etzer DaroutBMO Capital
Success Rate
4/12 ratings generated profit
33%
Average Return
-0.28%
reiterated a buy rating 4 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -0.28% per trade.
2 Years
Etzer DaroutBMO Capital
Success Rate
3/12 ratings generated profit
25%
Average Return
+5.20%
reiterated a buy rating 4 months ago
Copying Etzer Darout's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of +5.20% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CCCC Analyst Recommendation Trends

Rating
Dec 23
Jan 24
Feb 24
Mar 24
May 24
Strong Buy
7
8
7
3
3
Buy
1
1
2
2
2
Hold
6
5
6
5
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
14
15
10
10
In the current month, CCCC has received 5 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. CCCC average Analyst price target in the past 3 months is $11.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

CCCC Financial Forecast

CCCC Earnings Forecast

Next quarter’s earnings estimate for CCCC is -$0.36 with a range of -$0.46 to -$0.18. The previous quarter’s EPS was -$0.41. CCCC beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year CCCC has Underperformed its overall industry.
Next quarter’s earnings estimate for CCCC is -$0.36 with a range of -$0.46 to -$0.18. The previous quarter’s EPS was -$0.41. CCCC beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year CCCC has Underperformed its overall industry.

CCCC Sales Forecast

Next quarter’s sales forecast for CCCC is $4.78M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $3.04M. CCCC beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.63% of the time in the same period. In the last calendar year CCCC has Outperformed its overall industry.
Next quarter’s sales forecast for CCCC is $4.78M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $3.04M. CCCC beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.63% of the time in the same period. In the last calendar year CCCC has Outperformed its overall industry.

CCCC Stock Forecast FAQ

What is CCCC’s average 12-month price target, according to analysts?
Based on analyst ratings, C4 Therapeutics’s 12-month average price target is $11.00.
    What is CCCC’s upside potential, based on the analysts’ average price target?
    C4 Therapeutics has 121.77% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CCCC a Buy, Sell or Hold?
          C4 Therapeutics has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
            What is C4 Therapeutics’s price target?
            The average price target for C4 Therapeutics is $11.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $14.00 ,the lowest forecast is $8.00. The average price target represents 121.77% Increase from the current price of $4.96.
              What do analysts say about C4 Therapeutics?
              C4 Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of CCCC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis